Just 12 weeks of treatment eliminated hepatitis C virus in HIV patients.
SEATTLE -- Two drug combinations aimed at hepatitis C (HCV) yielded
almost perfect cure rates in patients also infected with HIV,
researchers reported here at the 2015 Conference on Retroviruses and Opportunistic Infections.
When the drugs were given for 12 weeks, 96% to 98% of patients had
undetectable HCV 12 weeks after the end of therapy -- the so-called
SVR12, which is regarded as a cure.
The only blot on the horizon was a 76% SVR12 rate when the combination of daclatasvir and sofosbuvir (Sovaldi) was given for just 8 weeks, reported David Wyles, MD, of the University of California San Diego.
Labels: CROI 2015, daclatasvir plus sofosbuvir, Harvoni, HIV-HCV coinfection, SVR12